Horizons ETFs Made Waves When They Launched the World’s First Psychedelics Stock ETF on the NEO Exchange Early This Year
The Dales Report sat down with Steve Hawkins, the President and CEO of Horizons ETFs for an interview, to learn a little bit more about the behind-the-scenes on creating a Psychedelics ETF like
Horizons Psychedelic Stock Index ETF (NEO: PSYK) from scratch, what investors should know, and where the Psychedelics industry – and others – might be headed. Right now, Hawkings says, the psychedelics industry resembles Cannabis in capital market structure. There’s very few companies in the space, but with big IPOs, and multiple U.S. companies that are looking at moving into Canadian space.
[co-author: Ilya Ross]
What is a SPAC?
Special Purpose Acquisition Companies, known as SPACs, are companies with no commercial operations set up by investors, and which
exist for the sole purpose of raising money through an initial public offering (IPO) to eventually acquire another company.
Sometimes known as “blank check companies,” SPACs are typically formed by a private equity sponsor that lists its common equities on a public stock exchange through an IPO, with the eventual goal of combining with private businesses. This creates a “back door” into the public markets since these private enterprises don’t need to go through the expense and hassle of their own IPO. Once public, a SPAC typically has two years to complete a deal or they must return their funds to investors. This timeframe for a business combination, the requirement to hold public money in trust, and other technical matters pertaining to a SPAC transaction are set contractually and by specific rules of
Poseidon Asset Management co-founder and managing director Morgan Paxhia recently spoke with Benzinga about some of the top low-cost buys on the market today, including several options investors could get for well under $100 per share.
Those with limited funds to invest might want to avoid a single shot stock, he advised. Those looking for beta exposure in the U.S. market, however, may want to consider
AdvisorShares Pure U.S. Cannabis ETF (NYSE:MSOS) to offset some risk with a diversified investment. I think it s just good financial sense, Paxhia, an investor since the age of 12, says.
Poseidon is one-half of one of the cannabis space s longest-running investment funds. Paxhia co-runs the firm with his sister, Emily. They have invested in some of market s top names, including
Zuber Lawler has been representing leading cannabis companies for 14 years handling initial public offerings (IPOs), M&As, finance, intellectual property, FDA and other regulatory work and litigation, in addition to representing a long list of iconic Fortune 500 companies, global funds and governmental entities in their international transactions.
Despite the country’s change in administration and widespread talk of federal legalization, the cannabis industry is complex. However, Zuber Lawler provides trusted and reliable legal representation to mitigate the complexity.
Well Decorated
Zuber Lawler’s accomplishments are many. The firm was recently named “Cannabis Law Firm of the Year” by Marijuana Venture Magazine and it obtained the second-ever-issued U.S. plant patent for a cannabis strain as well as U.S. utility patents on cannabis processes, machines and formulations. In addition, the firm obtained the first-ever issued “Generally Recognized as Safe” designati
One80 Makes Cannabis Buy-in with Cannasure Insurance Services Acquisition March 9, 2021
Cannabis is getting bigger, and now insuring cannabis seems to be a bigger deal, too. The cannabis-focused insurance space can now be counted as part of a larger trend in recently announced business deals in cannabis.
One80 Intermediaries announced on Tuesday it has acquired Cannasure Insurance Services, an Ohio-based wholesale broker and managing general agent focused on the cannabis and hemp industry.
Terms of the deal were not disclosed.
Despite the pandemic, sales in the cannabis industry saw a massive boost last year, rising 48% to $21.3 billion. Analytics firm BDSA now forecasts global cannabis sales will grow to $55.9 billion in 2026, a compound annual growth rate of more than 17%.